Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
Authors
Keywords
-
Journal
BLOOD
Volume 118, Issue 3, Pages 686-692
Publisher
American Society of Hematology
Online
2011-05-03
DOI
10.1182/blood-2010-12-319038
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia
- (2010) Francisco Cervantes et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib
- (2009) R. M. Lemoli et al. BLOOD
- Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib
- (2009) R. D. Press et al. BLOOD
- A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib
- (2009) S. K. McWeeney et al. BLOOD
- The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data
- (2009) V. G. Oehler et al. BLOOD
- Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
- (2009) A. Quintas-Cardama et al. BLOOD
- SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations
- (2009) D. Nowak et al. BLOOD
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
- Harmonization of molecular monitoring of CML therapy in Europe
- (2009) M C Müller et al. LEUKEMIA
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
- Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
- (2008) T. P. Hughes et al. BLOOD
- Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia
- (2008) W. Deenik et al. BLOOD
- Translation of the Philadelphia chromosome into therapy for CML
- (2008) B. J. Druker BLOOD
- Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
- (2008) S. Branford et al. BLOOD
- Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease
- (2008) Peter Valent BRITISH JOURNAL OF HAEMATOLOGY
- Chronic Myeloid Leukemia Stem Cells
- (2008) Edward Kavalerchik et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now